Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.earumpharma.com | |
Market Cap | 25.45 Cr. | |
Enterprise Value(EV) | 27.97 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 0.02 | Trailing Twelve Months Ending 2023-09 |
Price-Earning Ratio (PE) | 53.14 | Trailing Twelve Months Ending 2023-09 |
Industry PE | 38.37 | Trailing Twelve Months Ending 2023-09 |
Book Value / Share | 2.21 | Trailing Twelve Months Ending 2023-09 |
Price to Book Value | 0.47 | Calculated using Price: 1.03 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 24.71 Cr. | 247,111,618 Shares |
FaceValue | 2 | |
About Earum Pharmaceuticals Ltd. | ||
The company is engaged in the pharmaceutical business involving marketing, trading and distribution of wide range of pharmaceutical formulation products such as anti-biotic drugs, anti-malarial drugs, anti-allergic & anti cold drugs, analgesic/ anti-pyretic & anti inflammatory drugs, dermatology products, cerebral activator drugs, neurological drugs, gastro intestinal drugs, steroids, gynecology drugs, calcium, multivitamins, anti-oxidants and injections. Apart from pharmaceutical formulation products, it also deals in trading of active pharmaceutical ingredients (API's) such as Levofloxacin Hemihdrate IP, Albendazol IP, Amoxicillin Trihydrate IP etc. |
1 Day |
|
+4.04% |
1 Week |
|
+1.98% |
1 Month |
|
-7.21% |
3 Month |
|
+1.98% |
6 Month |
|
-50.48% |
1 Year |
|
-54.02% |
2 Year |
|
-90.41% |
5 Year |
|
|
10 Year |
|
8 years | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 7.15 | 11.05 | 30.94 | 32.17 | 17.83 | 0.61 | 14.24 | 11.18 | |
Return on Capital Employed (%) | 17.10 | 21.97 | 24.94 | 23.99 | 17.40 | 4.23 | 12.34 | 11.66 | |
Return on Assets (%) | 1.11 | 1.61 | 5.98 | 7.77 | 6.11 | 0.28 | 7.85 | 6.91 |
Particulars | 9 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 1 | 2 | 5 | 6 | 14 | 15 | 17 | 19 | 55 | |
Non Curr. Liab. | 0 | 1 | 2 | 3 | 1 | 2 | 0 | 0 | 0 | |
Curr. Liab. | 7 | 9 | 13 | 15 | 20 | 11 | 12 | 10 | 6 | |
Minority Int. | ||||||||||
Equity & Liab. | 9 | 11 | 20 | 23 | 36 | 28 | 29 | 29 | 60 | |
Non Curr. Assets | 0 | 0 | 0 | 0 | 4 | 1 | 1 | 0 | 0 | |
Curr. Assets | 9 | 11 | 19 | 23 | 32 | 27 | 28 | 28 | 60 | |
Misc. Exp. not W/O | ||||||||||
Total Assets | 9 | 11 | 20 | 23 | 36 | 28 | 29 | 29 | 60 |
Particulars | 9 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09 Rs. Cr. TTM |
Net Sales | 19 | 23 | 35 | 51 | 55 | 41 | 21 | 14 | 5 | |
Other Income | 0 | 0 | 0 | 0 | 2 | 9 | 8 | 2 | 2 | |
Total Income | 19 | 24 | 36 | 51 | 57 | 50 | 29 | 16 | 7 | |
Total Expenditure | -18 | -23 | -34 | -47 | -54 | -49 | -25 | -13 | -5 | |
PBIDT | 1 | 1 | 2 | 3 | 4 | 1 | 3 | 3 | 2 | |
Interest | 0 | -1 | -1 | -1 | -1 | -1 | 0 | 0 | -1 | |
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Taxation | 0 | 0 | 0 | -1 | -1 | 0 | -1 | -1 | -1 | |
Exceptional Items | ||||||||||
PAT | 0 | 0 | 1 | 2 | 2 | 0 | 2 | 2 | 0 | |
Adjusted EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Particulars | 8 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 0 | 0 | -7 | 0 | -3 | -7 | 3 | 0 | |
Cash Fr. Inv. | 0 | 0 | 0 | 0 | -3 | 3 | 0 | ||
Cash Fr. Finan. | 1 | 0 | 7 | 1 | 7 | 3 | -3 | 0 | |
Net Change | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | |
Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 |
Sat, 09 Dec 2023
Submission Of Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2023 Along With Limited Review Report Submission of Unaudited Financial Results for the Quarter and Half year ended on 30th September 2023 along with Limited review Report |
Sat, 09 Dec 2023
Board Meeting Outcome for Outcome Of The Board Meeting Held On Today I.E. 9Th December 2023 As Per Regulation 30 Of SEBI (LODR) Regulations 2015 Pursuant to second proviso to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Board of Directors of the Company in their meeting held today i.e. Saturday 9th December 2023 at the Registered Office of the Company which commenced at 3:00 P. M. and concluded at 4:30 P. M. inter-alia has consider and approve the Unaudited Financial Results of the Company for the Quarter and Half Year ended on 30th September 2023 along with Limited Review Report. |
Fri, 13 Oct 2023
Reg. 34 (1) Annual Report. Kindly find the attached Annual Report of the Company. |
Mon, 11 Dec 2023 |
|
|
|
|
|